Product
WZTL002-1
1 clinical trial
6 indications
Indication
Non-Hodgkin's Lymphomas, B-CellIndication
Diffuse Large B-cell LymphomaIndication
Primary Mediastinal B-cell LymphomaIndication
Transformed Follicular LymphomaIndication
Follicular LymphomaIndication
Mantle Cell LymphomaClinical trial
A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell LymphomasStatus: Recruiting, Estimated PCD: 2024-05-01